1. Home
  2. VET vs ANAB Comparison

VET vs ANAB Comparison

Compare VET & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vermilion Energy Inc.

VET

Vermilion Energy Inc.

N/A

Current Price

$10.91

Market Cap

1.7B

Sector

Energy

ML Signal

N/A

Logo AnaptysBio Inc.

ANAB

AnaptysBio Inc.

N/A

Current Price

$47.96

Market Cap

1.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VET
ANAB
Founded
1994
2005
Country
Canada
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.4B
IPO Year
2004
2015

Fundamental Metrics

Financial Performance
Metric
VET
ANAB
Price
$10.91
$47.96
Analyst Decision
Buy
Strong Buy
Analyst Count
6
8
Target Price
$15.39
★ $87.25
AVG Volume (30 Days)
★ 1.6M
382.4K
Earning Date
11-04-2026
11-24-2026
Dividend Yield
★ 3.66%
N/A
EPS Growth
N/A
★ 91.02
EPS
★ N/A
N/A
Revenue
N/A
★ $234,603,000.00
Revenue This Year
$41.51
N/A
Revenue Next Year
N/A
$69.42
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 157.01
52 Week Low
$7.76
$32.96
52 Week High
$14.82
$73.30

Technical Indicators

Market Signals
Indicator
VET
ANAB
Relative Strength Index (RSI) 37.27 48.62
Support Level $9.93 $44.25
Resistance Level $10.92 $51.54
Average True Range (ATR) 0.51 1.72
MACD -0.28 0.24
Stochastic Oscillator 24.82 49.28

Price Performance

Historical Comparison
VET
ANAB

About VET Vermilion Energy Inc.

Vermilion Energy Inc is an international oil and gas-producing company. The company engages in full-cycle exploration and production programs that focus on the acquisition, exploration, and development of liquids-rich natural gas in Canada and conventional natural gas in Europe while optimizing low-decline oil assets. Its operating segments are: Canada, France, Netherlands, Germany, Ireland, Australia, and CEE, each representing the oil and gas exploration operations at its assets located in these regions. The company mainly derives revenue from the production and sale of petroleum and natural gas. The majority of its revenue is generated from Canada, where the company's operations are mainly focused on the Deep Basin trend in the West Pembina region of Alberta and on the Mica property.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: